Although many studies assessed the levels of Lp (a) in CAD patients, our study provides assessment of their levels using a cumulative risk classification adopted by the national lipid association [20] including patients with and without CAD with various risks to develop ASCVD. The gene discussed is LPA; the disease is coronary artery disorder.